What Stoke announced
Stoke Therapeutics reported that dose escalation is continuing in its Phase 1 OSPREY study of STK-002, an investigational RNA medicine being developed for autosomal dominant optic atrophy (ADOA). According to the company’s October 30 business update, dosing has been completed in the study’s first two cohorts, while participants in a third cohort are currently being dosed. A fourth cohort is expected to begin in early 2027.
Stoke said it expects initial safety and efficacy findings from OSPREY during the first half of 2027. The announcement did not provide participant-level results, vision measurements, adverse-event information, or other clinical data from the study.
Why this is relevant to the vision-loss community
ADOA is an inherited optic nerve disorder that can cause progressive vision loss. Stoke describes STK-002 as a program intended to address protein haploinsufficiency associated with the condition. Haploinsufficiency refers to a situation in which one working copy of a gene does not produce enough of a needed protein.
The company said STK-002 is being studied as a possible treatment for people with ADOA and characterized the program as targeting the underlying protein shortfall. However, this is an early-stage clinical study. The update does not establish that STK-002 improves vision, slows vision loss, or is safe and effective for patients.
For families and clinicians following inherited retinal and optic nerve disease research, the update provides a timeline for when early human-study information may become available. It also indicates that Stoke is still assessing different dose levels, a common part of early-phase research intended to gather safety, dosing, and preliminary activity information.
What is known about the study update
In the company’s announcement, Stoke stated that the first two OSPREY dosing cohorts had finished dosing and that the third cohort was underway. It also stated that it anticipates moving to a fourth cohort in early 2027.
The company expects to report initial safety and efficacy data in the first half of 2027. The source material does not describe the number of participants in OSPREY, the doses being evaluated, eligibility criteria, study locations, the specific visual or functional outcomes being measured, or how long participants will be followed.
The announcement was primarily a quarterly financial and business update. Alongside the ADOA program, it described progress in Stoke’s separate Phase 3 program for zorevunersen in Dravet syndrome, a developmental neurological condition. That program is distinct from STK-002 and ADOA.
Important limitations
This information comes from a company press release rather than a peer-reviewed research report or a presentation of trial results. No OSPREY outcome data were included in the published update. As a result, it is not yet possible to assess the treatment’s potential risks, the consistency of any findings, or whether any observed changes would be clinically meaningful.
STK-002 remains investigational and has not been established as a treatment for ADOA in this announcement. Stoke’s expected first-half 2027 timing is a company-provided projection and may change.